Immunohistochemistry Study Urothelial Carcinoma using Tumor Markers (EGFR, EMA and CD117)
Ebtihal Chiad Abass, Alaa Salah Jumaah, Kaswer Musa Jaafar Altoriah, Hawraa Sahib Al-Haddad, Aseel Al-Quzweni, Hussein Raof Alghaszali, Najah R. Hadi.
The aim of the present is to determine the immunohistochemical expression of EGFR, EMA and CD117 in case of urinary bladder transitional cell carcinoma and their relation with staging of tumor and its impact on further prognosis. EGFR immunohistochemical study showing (61.5 %) positive in case of urinary bladder carcinoma with significant difference between staging of tumor (p value 0.019) with signification expression between low grade and high grade tumor with P value 0.002 (6.2%) positivity in high grade versus (15.4 %) positivity in low grade). EMA showing strong positivity in urothelial carcinoma 96.2% without significant difference between staging and grading of tumor with p valve of (0.57) and (0.227) respectively CD117 immunohistochemical study showing total positive cases of urinary bladder carcinoma of 69.2% with significant difference in comparison with staging and grading of tumor with (P-value=0.00) for each respectively. Our result demonstrate that EGFR and CD 117 immunohistochemical staining showing strong positivity in majority of urothelial carcinoma cases with significant relation to both pathological grading and staging of tumor. Application of both markers may play a role to give idea about behavior of tumor and possibility of further recurrence with and even direct therapy application EMA showing strong positive expression which give idea about tumor origin from epithelial lining. It had no benefit in assessment of tumor grading and staging